地塞米松与临床显著术后恶心呕吐:PADDI随机试验预设亚组分析
该预设亚组分析纳入1466例非急诊非心脏手术患者,比较地塞米松8 mg与安慰剂对临床显著PONV的影响。主要结局(术后第1或2天临床显著PONV)无显著差异(RR=0.79,95%CI 0.56-1.11,P=0.18),但地塞米松降低了第2天严重PONV发生率(RR=0.58,95%CI 0.37-0.92,P=0.02)。
要点
- 地塞米松8 mg静脉注射未显著减少临床显著PONV。
- 地塞米松降低术后第2天严重PONV发生率,NNT=36.7。
- 地塞米松组恶心评分更低、止吐药使用更少、呕吐事件更少。
核心结论
- 地塞米松8 mg静脉注射不影响临床显著PONV,但降低PONV发生率和严重程度,并减少止吐药使用。
研究设计与样本
- PADDI随机对照试验的预设嵌套优效性亚组分析,纳入1466例非急诊非心脏手术患者,地塞米松组733例、安慰剂组733例。
主要发现
- 主要结局(术后第1或2天临床显著PONV)地塞米松组52例(7.1%),安慰剂组66例(9%),RR=0.79,95%CI 0.56-1.11,P=0.18。
- 术后第2天严重PONV地塞米松组27例(3.9%),安慰剂组47例(6.7%),RR=0.58,95%CI 0.37-0.92,P=0.02,NNT=36.7(95%CI 20-202)。
- 在全部8880例PADDI患者中,地塞米松组至术后第2天恶心评分更低、止吐药使用更少、呕吐事件更少。
临床怎么用
- 地塞米松8 mg静脉注射可用于降低PONV严重程度和止吐药需求,但不应期望其减少临床显著PONV。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinically significant postoperative nausea and vomiting (PONV) is a patient-reported outcome which reflects patient experience. Although dexamethasone prevents PONV, it is unknown what impact it has on this experience. METHODS: In this prespecified embedded superiority substudy of the randomised Perioperative Administration of Dexamethasone and Infection (PADDI) trial, patients undergoing non-urgent noncardiac surgery received dexamethasone 8 mg or placebo intravenously after induction of anaesthesia, and completed a validated PONV questionnaire. The primary outcome was the incidence of clinically significant PONV on day 1 or day 2 postoperatively. Secondary outcomes included the incidence of clinically significant PONV and severe PONV on days 1 and 2 considered separately. RESULTS: A total of 1466 participants were included, with 733 patients allocated to the dexamethasone arm and 733 to matched placebo. The primary outcome occurred in 52 patients (7.1%) in the dexamethasone arm and 66 (9%) patients in the placebo arm (relative risk [RR]=0.79; 95% confidence interval [CI], 0.56-1.11; P=0.18). Severe PONV occurred on day 2 in 27 patients (3.9%) in the dexamethasone arm and 47 patients (6.7%) in the placebo arm (RR=0.58; 95% CI, 0.37-0.92; P=0.02; number needed-to-treat (NNT)=36.7; 95% CI, 20-202). In the entire cohort of 8880 PADDI patients, lower nausea scores, less frequent administration of antiemetics, and fewer vomiting events were recorded by patients in the dexamethasone arm up to day 2 after surgery. CONCLUSIONS: Administration of dexamethasone 8 mg i.v. did not influence clinically significant PONV. Dexamethasone administration did, however, decrease the incidence and severity of PONV, and was associated with less frequent administration of antiemetic agents. CLINICAL TRIAL REGISTRATION: ACTRN12614001226695.
引用
- Corcoran TB, Martin C, O'Loughlin E, et al. Dexamethasone and clinically significant postoperative nausea and vomiting: a prespecified substudy of the randomised perioperative administration of dexamethasone and infection (PADDI) trial. Br J Anaesth. 2022. PMID: 35803757. doi:10.1016/j.bja.2022.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。